Risk-Based Approaches to CGT Clinical Trials Under E6(R3): A New Path Forward

When minutes matter in cell and gene therapies (CGT), traditional clinical trial approaches simply don't cut it. E6(R3) changes everything.

New Framework: E6(R3) Reimagines Risk Assessment

Let's face it – cell and gene therapy isn't just another pharmaceutical product. It's a revolution that demands revolutionary approaches to quality and compliance. The E6(R3) guideline isn't merely an update; it's a complete reimagining of how we assess risk throughout clinical trials.

This shift couldn't come at a better time. The CGT market is exploding – from \$21.28 billion last year to a projected \$177.46 billion by 2034, growing at an impressive 18.7% annually.1

The E6(R3) good clinical practice (GCP) guideline gives us something the CGT world desperately needs: a flexible, intelligent framework that focuses resources where risks are highest, not where tradition says they should be.

Ready to revolutionize your approach to CGT manufacturing? Download our Ultimate Guide to see how digital systems are transforming quality and compliance.

CGT-Specific Risks: Why Traditional Approaches Fall Short

Cell and gene therapy manufacturing isn't just complicated – it's fundamentally different. Here's why E6(R3)'s risk-based approach fits perfectly:

1. Chain of Identity Challenges

When your starting material is literally your patient, maintaining identity through dozens of complex manufacturing steps isn't just good practice – it's absolutely critical.

2. The Race Against Time

In CGT manufacturing, every minute counts. Aligning with E6(R3) focuses your quality control where it matters most, potentially cutting batch release times without cutting corners.

3. Starting Material Variability

No two patient samples are identical. Risk-based approaches acknowledge this reality instead of forcing standardization where it doesn't belong.

4. Severe Capacity Constraints

Here's a sobering statistic: only 5%-10% of the manufacturing capacity needed to commercialize CGT products at scale currently exists.2 When resources are this limited, you can't afford to waste them on low-risk processes.

5. Complex Outsourced Networks

With an estimated 90% of CGT production being outsourced, supply chains aren't just a chain – they're intricate webs. E6(R3) provides a framework to identify and mitigate the most critical risks across these extended networks.

Digital Risk Management: Real-Time Insights When They Matter Most

Paper records and legacy systems can't keep pace with CGT manufacturing. They just can't. Modern risk management requires digital solutions that deliver insights when they actually matter – in real-time, not weeks later during review.

MasterControl's Manufacturing Excellence (Mx) platform transforms risk management from periodic review to continuous oversight:

• See risks as they emerge, not after they've become problems.

• Connect quality systems with manufacturing execution for truly integrated compliance.

• Slash data integrity errors by 90% compared to manual processes.

• Standardize risk assessment across multiple sites and batches.

As Kyle Jackson, Director of Manufacturing at Dendreon, puts it: "If I get a call inevitably in the middle of the night that something's going wrong, I log into my MasterControl. I know exactly what's happening, where they're at the process—nothing is getting lost in translation—and so it's really easy for us to troubleshoot remotely for complex process issues."3

That's not just convenience – it's the difference between saving and losing a life-saving therapy.

Transform your approach to risk management. Download our Ultimate Guide to see how modern digital systems are revolutionizing CGT manufacturing.

Review by Exception: Focus on What Actually Matters

Let's be honest – those hundred-page batch records aren't getting thorough reviews. They're getting skimmed at best. Review by exception changes that paradigm entirely.

What if you could focus only on the 1% that went wrong instead of reviewing the 99% that went right?

MasterControl's Manufacturing Excellence makes this possible by:

• Highlighting deviations that require your attention.

• Automatically validating data within specifications.

• Drawing your eye to what actually matters.

The impact? A stunning 75% reduction in batch review time. For patients waiting for life-saving CGT therapies, that's not just an efficiency metric – it could be the difference between life and death.

Quality Impact: Better Compliance, Better Therapy Outcomes

Implementing risk-based approaches under E6(R3) with powerful digital tools like MasterControl doesn't just tick regulatory boxes – it fundamentally transforms your operations. The numbers tell the story:

• 75% faster batch reviews get therapies to patients when they need them.

• 90% fewer data integrity errors mean more reliable clinical data.

• 25% reduction in deviations translates to more consistent product quality.

These improvements attack a critical bottleneck: quality testing and batch release currently eat up to 70% of manufacturing lead time in CGT production, largely due to manual processes and paper documentation.4

E6(R3) gives us permission to be smarter about quality. Digital tools give us the means to actually do it.

See the metrics for yourself. Download our Ultimate Guide to learn how purpose-built digital tools are transforming CGT manufacturing.

Future-Proofing CGT Clinical Trials: What Comes Next

The CGT field isn't slowing down – with over 2,800 companies developing therapies across the globe, the pace of innovation is only accelerating. Embracing risk-based approaches under E6(R3) isn't just smart compliance – it's essential strategy.

Tomorrow's CGT leaders will be those who can:

1. Scale manufacturing capacity efficiently as demand explodes.

2. Navigate global regulatory expectations with confidence.

3. Accelerate innovation without compromising quality.

4. Deliver therapies to patients faster than competitors.

The mantra for success is clear: "Right First Time. Right On Time." Risk-based approaches under E6(R3), enabled by digital solutions like MasterControl, make this possible even in the most complex CGT environments.

From Burden to Breakthrough: The E6(R3) Opportunity

E6(R3) isn't just another regulatory burden – it's an invitation to fundamentally rethink how we approach quality and compliance in cell and gene therapy manufacturing.

By focusing resources where risks are greatest, streamlining low-risk processes, and leveraging digital tools for real-time monitoring, you can simultaneously improve compliance, enhance product quality, and accelerate patient access to life-saving therapies.

As our industry guide notes, "The full impact of manufacturing process automation is realized when manufacturers can correlate production, supplier, and quality data for actionable insights."

This isn't just about better compliance – it's about better medicines and better lives for those who can benefit from CGT therapy.

Ready to transform your CGT manufacturing operations? Download our Ultimate Guide to start your digital journey today.

References:

1. "Cell and Gene Therapy market Size, Share and Trends 2025 to 2034," Precedence Research, July 14, 2025.

2. "Introducing biosimilar competition for cell and gene therapy products," Brian Canter, et al, Journal of Law and the Biosciences, July 15, 2024.

3. MasterControl Case Study: Dendreon.

4. "Dare to be Different: It's Time to Revamp Collaboration in Life Sciences Contract Manufacturing," Accenture Life Sciences.